ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cage Bio, a drug delivery company that focuses on ionic liquids, has launched with $7.2 million in series A funding. The company will use the funds to continue developing a product to treat papulopustular rosacea, a skin disease. Ionic liquids are salts with poorly coordinated ions, which allows them to be liquid at room temperature. Cage says ionic liquids can be used instead of organic solvents to deliver drugs through the skin.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter